Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients.


This retrospective study evaluated the efficiency and tolerance of rituximab in the management of resistant myasthenia gravis (MG). All patients who received rituximab for the treatment of MG between 2004 and 2015 at Pitié-Salpétrière University Hospital (Paris, France) were included. The efficacy of rituximab was evaluated every 6 months by the myasthenic… (More)
DOI: 10.1016/j.nmd.2016.12.004